REG - AstraZeneca PLC - AZ and Luye Pharma complete agreement for Seroquel

AstraZenecaAnnouncement

28/06/2018 13:30

RNS Number : 9345S
AstraZeneca PLC
28 June 2018
 


28 June 2018 13:30 BST
 
Agreement with Luye Pharma Group for rights to Seroquel and Seroquel XR

in the UK, China and other international markets completed
 
AstraZeneca today completed an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.
 
Under the terms of the agreement, AstraZeneca has received a payment of $260m from Luye Pharma as part of the total $538m consideration. Further payments of $240m and $38m are due in December 2019 and July 2020, respectively, and a milestone payment is also due on the successful transition of certain activities to Luye Pharma. The present value of the upfront and future payments will be reported as Other Operating Income in the Company's financial statements in the second quarter of 2018.
 
About Seroquel
Seroquel (quetiapine fumarate, immediate release, IR) and Seroquel XR (extended release formulation) are atypical, anti-psychotic medicines with antidepressant properties. The main indications for Seroquel are the treatment of schizophrenia and bipolar disorder. Seroquel XR is also approved in some markets for major depressive disorder and generalised anxiety disorder.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
 
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
 




Media Relations


 


 




Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 
 


+44 203 749 5712




Josie Afolabi


 


+44 203 749 5631




Craig Marks


Finance; Fixed Income; M&A


+44 7881 615 764




Henry Wheeler


Oncology


+44 203 749 5797




Mitchell Chan


Oncology; Other


+1 240 477 3771




Christer Gruvris


Brilinta; Diabetes


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free


 


+1 866 381 7277




 


 


 




 
Adrian Kemp
Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRLVLFLVQFBBBD